Our studies reveal that adipocyte-mediated upregulation of GAL-9 on B-ALL cells can be targeted with antibody-based therapies to overcome obesity-induced chemoresistance. The gene discussed is LGALS9; the disease is obesity due to melanocortin 4 receptor deficiency.